

# Sanofi Pipeline – Solid Tumors

## Phase



### Cemiplimab\* (PD-1 monoclonal antibody) Immunomodulatory agent

Adjuvant Cemiplimab Vs Placebo After Surgery and RT in Patients with High-Risk CSCC (C-Post)	Phase I	Phase II	Phase III
Neoadjuvant Cemiplimab in Patients with Resectable NSCLC, HCC and HNSCC	Phase I	Phase II	Phase III
Neoadjuvant Cemiplimab in Patients with Stage II to IV (M0) CSCC	Phase I	Phase II	Phase III
A Non-Interventional, Multicenter, Observational Study with Cemiplimab in Patients with advanced CSCC (CemiSkin)	Phase I	Phase II	Phase III
A Non-Interventional, Multinational, Observational Study with Cemiplimab in Patients with NSCLC (Cemi-Lung)	Phase I	Phase II	Phase III

### Tusamitamab ravtansine (Maytansine-loaded CEACAM5 monoclonal antibody) Immunomodulatory agent

Tusamitamab ravtansine Vs Docetaxel in Patients with Metastatic NSq NSCLC (CARMEN-LC03)	Phase I	Phase II	Phase III
Tusamitamab ravtansine in Combination with Ramucirumab in Pre-Treated Patients with NSq NSCLC (CARMEN-LC04)	Phase I	Phase II	Phase III
Tusamitamab ravtansine in Combination with Pembrolizumab and Tusamitamab ravtansine in Combination with Pembrolizumab and Platinum-based Chemotherapy with or without Pemetrexed in Patients with NSq NSCLC (CARMEN-LC05)	Phase I	Phase II	Phase III
Tusamitamab ravtansine in Patients with NSq NSCLC with negative or moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06)	Phase I	Phase II	Phase III
Tusamitamab ravtansine in Combination with Ramucirumab in Patients with CEACAM5-Positive Gastric Cancer (CARMEN-GC01)	Phase I	Phase II	Phase III
Tusamitamab ravtansine in Patients with CEACAM5-Positive Advanced Breast and Pancreatic Tumors (CARMEN-BT01)	Phase I	Phase II	Phase III

### SAR442720 (RMC-4630)\*\* (SHP2 inhibitor) Small molecule

SAR442720 in Combination with Sotorasib in Patients with KRAS G12C Mut NSCLC	Phase I	Phase II	Phase III
SAR442720 in Combination with Pembrolizumab or Adagrasib in Patients with Advanced Malignancies	Phase I	Phase II	Phase III

### SAR444245 (non-alpha IL-2) Immunomodulatory agent

SAR444245 alone and in Combination with a ICI or EGFR Antibody in Patients with Advanced or Metastatic Solid Tumors FIH#	Phase I	Phase II	Phase III
SAR444245 in Combination with Cemiplimab for the Treatment of Patients with Advanced Unresectable or Metastatic Skin Cancers (Pegathor Skin 201)	Phase I	Phase II	Phase III

### Alomfilimab (SAR445256/KY1044)### (anti-ICOS monoclonal antibody) Immunomodulatory agent

Alomfilimab (SAR445256/KY1044) in Combination with Atezolizumab for the Treatment of Patients with Advanced Malignancies	Phase I	Phase II	Phase III
--	---------	----------	-----------

### SAR444881 (BND-22) (anti-ILT2 monoclonal antibody) Immunomodulatory agent

SAR444881 (BND-22) for the Treatment of Patients with Advanced Solid Tumors§	Phase I	Phase II	Phase III
--	---------	----------	-----------

### SAR443579 (anti-NKp46/CD123 bispecific monoclonal antibody) Cell therapy

SAR443579 for the Treatment of Patients ≥ 12 Yrs of Age with RR AML, B-Cell ALL or High-Risk MDS FIH Study	Phase I	Phase II	Phase III
--	---------	----------	-----------

#### Study sponsors, collaborators and trademarks

- \* Regeneron in collaboration with Sanofi
- \*\* In collaboration with REVOLUTION medicines, also known as RMC-4630
- # Other collaborations or institutions
- ### Sponsored by Kymab Limited, a Sanofi company
- § Sponsored by Kadmon, a Sanofi company

The uses of the compounds described in these studies are investigational and the safety and efficacy of these uses have not been evaluated by any regulatory authority.



#### Abbreviations

ALL = acute lymphoblastic leukemia; CD123 = cluster of differentiation 123; CEA(CAM5) = carcinoembryonic antigen (-related cell adhesion molecule 5); CSCC = cutaneous squamous cell carcinoma; EGFR = epidermal growth factor receptor; FIH = first-in-human; HCC = hepatocellular carcinoma; HNSCC = head and neck squamous cell carcinoma; ICI = Immunecheckpoint-Inhibitor; ICOS = inducible T-cell co-stimulator; IL = interleukin; ILT2 = immunoglobulin-like transcript 2; IV = intravenous; KRAS G12C Mut = mutation of the G protein KRAS; MDS = myelodysplastic syndrome; Mut = mutant; Nkp46 = NK cell protein with 46 kilodaltons; (NSq) NSCLC = (non-squamous) non-small cell lung cancer; PD-1 = programmed cell death protein-1; RR AML = relapse/refractory acute myeloid leukemia; RT = radiotherapy; SHP2 = Src homology 2-containing protein tyrosine phosphatase 2.